Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Breast Neoplasms 13126Neoplasms 10474Carcinoma, Non-Small-Cell Lung 6863Prostatic Neoplasms 6265Colorectal Neoplasms 5940Lung Neoplasms 5097Multiple Myeloma 3573Pancreatic Neoplasms 3558Leukemia, Myeloid, Acute 3507Neoplasm Metastasis 3505Carcinoma, Hepatocellular 3269Ovarian Neoplasms 3166Melanoma 3138Stomach Neoplasms 3055Lymphoma 2982Head and Neck Neoplasms 2599Recurrence 2553Precursor Cell Lymphoblastic Leukemia-Lymphoma 2497Leukemia 2361Colonic Neoplasms 2327Brain Neoplasms 2308Lymphoma, Non-Hodgkin 2268Rectal Neoplasms 2190Uterine Cervical Neoplasms 2187Glioblastoma 2012Leukemia, Lymphocytic, Chronic, B-Cell 1992Carcinoma, Renal Cell 1912Squamous Cell Carcinoma of Head and Neck 1878Lymphoma, Follicular 1847Esophageal Neoplasms 1799

Interventions

toripalimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Primary Condition: Advanced Tumors × Clear all
NCT05650203 2023-04-05

A Study of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Patients With Advanced Malignancies

Shanghai Junshi Bioscience Co., Ltd.

Phase 1 Withdrawn
Other neoplasm

Primary Condition: Advanced Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡